BD Neopak™ XtraFlow™ Glass Prefillable Syringe

A next‑generation injectable system has been engineered to optimize the administration of viscous and higher‑volume therapies. Its design features an 8 mm needle paired with thin‑wall technology, which significantly lowers the likelihood of accidental intramuscular injection—reducing risk by a factor of 2.5 to 8 compared with commonly used longer needle configurations, without increasing intradermal risk. The needle structure also offers improved robustness, withstanding higher bending and buckling forces than standard thin‑wall options.

User studies indicate strong preference for this configuration, particularly when injecting formulations of 10cP or 30cP, and participants reported reduced needle‑related anxiety during self‑injection. Performance modeling demonstrates meaningful efficiency gains, including up to a 46% reduction in required injection force and up to a 57% decrease in injection time for viscous solutions. Multiple format options and compatibility with existing device platforms make the system adaptable for a range of therapeutic needs and development pathways.